GW 274150

12/01/2010 - "Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache."
12/01/2010 - "This study investigated the efficacy and tolerability of the highly selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. "
02/01/2012 - "However, despite high selectivity and potency, the iNOS inhibitor GW274150 was not effective for acute treatment or prophylaxis of migraine, suggesting that iNOS is very unlikely to be a promising target."
12/01/2010 - "GW274150 at doses predicted to inhibit iNOS >80% did not differ from placebo in the prophylaxis of migraine. "
12/01/2010 - "In Part 2, female patients with migraine received GW274150 60 mg (n= 160) or placebo (n = 154) once daily for 12 weeks. "

01/01/2021 - "Here, we show that iNOS knockout mice and mice treated with the clinically tested iNOS inhibitor GW274150 are protected against muscle wasting in models of both septic and cancer cachexia. "
01/30/2017 - "ALA-PDT with a 633 nm light source caused a significant reduction in post-irradiation tumor growth relative to light-only controls, which was further reduced by administration of 1400W or GW274150, whereas 1400W had little or no effect on controls. "

11/15/2007 - "We evaluated the selective and potent iNOS inhibitor GW274150 in asthma. "
12/01/2012 - "In the clinical setting, inhaled corticosteroids and phosphodiesterase 4 inhibitors are relatively effective against most features of asthma whereas the iNOS inhibitor GW274150 was ineffective. "

01/10/2005 - "We propose that selective inhibition of iNOS activity with GW274150 may be useful in the treatment of inflammatory bowel disease."

10/18/2002 - "Furthermore, radiographic signs of protection against bone resorption were present in the joints of iNOS-WT mice treated with GW274150 as well as in the joint from iNOS-KO mice. "